Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
$MGTA
Biotechnology: Pharmaceutical Preparations
Health Care
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/25/2022 | $2.00 | Buy → Neutral | Goldman |
| 1/24/2022 | $13.00 → $6.00 | Buy | B. Riley Securities |
| 1/6/2022 | $7.00 → $8.00 | Neutral → Buy | Goldman Sachs |
| 8/20/2021 | $7.00 | Neutral | Goldman |
| 8/3/2021 | $16.00 → $7.00 | Overweight → Neutral | JP Morgan |
| 7/22/2021 | $21.00 → $19.00 | Buy | B. Riley Securities |
| 6/29/2021 | $20.00 | Overweight | Cantor Fitzgerald |
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company's R&D Committee and Nominating and Corporate Governance Committee. "We are delighted to welcome Mike Vasconcelles to the Magenta board," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "Dr. Vasconcelles brings deep experience in research, medical operations, clinical trial design
Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company's Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives. Dr. Humphrey is a medical oncologist with significant leadership experience in drug development and has been involved with the development of more than 20 drug candidates, including regulatory submissions leading to multiple drug approvals in the United States and Europe. "As Magenta continues to advance our clinical and pr
Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first Chief Commercial Officer. "Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "I look forward to working with her in establishing this new functionality as Magenta prepares to enter the next stage of pipeline and product candidate development." As Chief
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
Goldman downgraded Magenta Therapeutics from Buy to Neutral and set a new price target of $2.00
B. Riley Securities reiterated coverage of Magenta Therapeutics with a rating of Buy and set a new price target of $6.00 from $13.00 previously
Goldman Sachs upgraded Magenta Therapeutics from Neutral to Buy and set a new price target of $8.00 from $7.00 previously
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
S-1/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh
– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory alignment – – CD45 antibody-drug conjugate (CD45-ADC) IND-enabling studies are advancing – – MGTA-145 clinical trial for stem cell mobilization in sickle cell disease patients is progressing with data now expected to be shared H1 2023 – – Conference call and webcast scheduled for 8:30am ET / 7:30am CT on December 13, 2022 – CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NAS
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting. The oral presentation at ASH, entitled "MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants
CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta") today announced completion of the merger with Dianthus Therapeutics, Inc. ("Dianthus") following Magenta's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta's common stock immediately prior to the merger. Magenta following the merger is referred to herein as the "combined company." Steve Mahoney, President and Chief Financial and Operating Officer of Magenta said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for th
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus' new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications Companies will host a joint webcast today, May 3, 2023 at 8:30 a.m. ET
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly. NovaBay Pharmaceuticals, Inc. (NYSE:NBY) shares climbed 62.9% to $1.01 after the company granted Biostem Technologies the right to commercialize amniotic tissue allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Plus Therapeutics, Inc. (NASDAQ:PSTV) surged 38% to $1.9167. Plus Therapeutics received $1.9 million advance payment from CPRIT. Avantax, Inc. (NASDAQ:AVTA) rose 27.5% to $25.45 as the company agreed to be acquired b
Tenon Medical, Inc. (NASDAQ:TNON) fell 34.3% to $0.1649 in pre-market trading as the company reported a proposed public offering of common stock. Axcella Health Inc. (NASDAQ:AXLA) fell 20.8% to $0.7762 in pre-market trading after jumping more than 70% on Friday. Courtside Group, Inc. (NASDAQ:PODC) shares fell 13% to $3.82 in pre-market trading after declining 45% on Friday. Impel Pharmaceuticals Inc. (NASDAQ:IMPL) shares fell 10% to $0.3788 in pre-market trading after gaining 10% on Friday. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) fell 9.8% to $5.50 in pre-market trading. Nuwellis, Inc. (NASDAQ:NUWE) fell 8.3% to $1.76 in pre-market trading after gaining around 7% on Friday. Hitek